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Kim de Jong1,3, H Marike Boezen1,3, Nick HT ten Hacken2,3, Dirkje S Postma2,3, Judith M Vonk1,3*
and the LifeLines cohort studyAbstract
Background: Lung growth in utero and lung function loss during adulthood can be affected by exposure to
environmental tobacco smoke (ETS). The underlying mechanisms have not been fully elucidated. Both ETS exposure
and single nucleotide polymorphisms (SNPs) in Glutathione S-Transferase (GST) Omega genes have been associated
with the level of lung function. This study aimed to assess if GSTO SNPs interact with ETS exposure in utero and
during adulthood on the level of lung function during adulthood.
Methods: We used cross-sectional data of 8,128 genotyped participants from the LifeLines cohort study. Linear
regression models (adjusted for age, sex, height, weight, current smoking, ex-smoking and packyears smoked) were
used to analyze the associations between in utero, daily and workplace ETS exposure, GSTO SNPs, the interaction
between ETS and GSTOs, and level of lung function (FEV1, FEV1/FVC). Since the interactions between ETS and GSTOs
may be modified by active tobacco smoking we additionally assessed associations in never and ever smokers
separately. A second sample of 5,308 genotyped LifeLines participants was used to verify our initial findings.
Results: Daily and workplace ETS exposure was associated with significantly lower FEV1 levels. GSTO SNPs
(recessive model) interacted with in utero ETS and were associated with higher levels of FEV1, whereas the
interactions with daily and workplace ETS exposure were associated with lower levels of FEV1, effects being more
pronounced in never smokers. The interaction of GSTO2 SNP rs156697 with in utero ETS associated with a higher
level of FEV1 was significantly replicated in the second sample. Overall, the directions of the interactions of in utero
and workplace ETS exposure with the SNPs found in the second (verification) sample were in line with the first
sample.
Conclusions: GSTO genotypes interact with in utero and adulthood ETS exposure on adult lung function level, but
in opposite directions.
Keywords: Genes, Environmental tobacco smoke, Lung functionBackground
Lung function loss is common in chronic respiratory
diseases like chronic obstructive pulmonary disease
(COPD), cystic fibrosis (CF) and interstitial lung fibrosis,
and associates with all-cause and other specific mortality
[1,2]. Both environmental and genetic factors contribute
to lung function loss. Active cigarette smoking is regarded
as the most important environmental risk factor, yet other* Correspondence: j.m.vonk@umcg.nl
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reproduction in any medium, provided the orfactors exist. Like active smoking, passive cigarette smoking
or environmental tobacco smoke (ETS) exposure induces
inflammation and oxidative stress in the lungs [3]. ETS
exposure has been associated with reduced level of lung
function at birth [4,5] and in adulthood [6,7], as well as
with respiratory symptoms [8,9] and increased COPD
risk [10,11]. In other words, ETS exposure can affect in
utero lung development, lung growth during childhood
and lung function loss during adulthood. However, the
underlying mechanisms have not been elucidated. Fur-
thermore, these underlying mechanism are not necessarily
similar for ETS exposure in utero and during adulthoodl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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period of exposure within the life-span are different.
Although it has been very well established that genetic
factors contribute to lung function level [12], less is known
about how genetic factors modify effects of ETS exposure
on the level of lung function during the life-span. Glutathi-
one S-Transferases (GSTs) are a family of enzymes involved
in the detoxification of xenobiotic substances such as
tobacco smoke, and play an essential role in oxidative
stress reactions [13,14]. Polymorphisms in the GST-mu, -pi,
and -theta genes have been described to interact with
tobacco smoke exposure with respect to asthma develop-
ment and atopy in asthmatic children [15,16] and lower
childhood level of lung function [17]. The GST-omega
(GSTO) class has been less well studied. Of interest, GSTO
enzymes have thioltransferase activity and can catalyze
specific reduction reactions with compounds that are not
substrates for other GSTs, suggesting an important role
for GSTO in oxidative stress reactions [18,19] and in
biotransformation of inorganic arsenic [20], a component
present in tobacco smoke. GSTO1 has also been reported
to activate IL-1β [21], a cytokine that is important for
tobacco smoke induced inflammation and fibrosis [22,23].
Harju et al. showed that GSTO1 is abundantly expressed
in alveolar macrophages [24]. Furthermore, a genome wide
association analysis in the Framingham Heart Study found
a GSTO2 SNP (rs156697) to be associated with both lower
level of FEV1 and FVC [12]. Another study could not
replicate this association between rs156697 and FEV1,
but found an association with COPD, defined by lower
lung function [25]. It is unknown whether GSTO1 and
GSTO2 SNPs modify effects of ETS exposure on the level
of lung function.
This study aimed to assess if GSTO SNPs interact with
in utero and/or adulthood ETS exposure on lung function
level in a general population.
Methods
Study sample and measurements
We included 8,128 genetically unrelated individuals from
the LifeLines cohort study. The LifeLines cohort is designed
to investigate universal risk factors and their modifiers for
multifactorial chronic diseases and comorbidities [26].
All subjects received a questionnaire and underwent a
medical examination including collection of a blood sample
for DNA extraction. The questionnaire included questions
regarding personal characteristics, smoking habits and ETS
exposure. We used self-reported in utero ETS exposure
(coded as: no/yes/do not know), daily ETS exposure based
on self-reported hours of exposure to other person’s
tobacco smoke per day (coded as: <1/≥1 hour per day),
and ETS exposure at work (answer categories: no/yes/not
applicable). The medical examination included spirometry
(FEV1 and FEV1/FVC) performed in a standardized settingfollowing ATS guidelines using a Welch Allyn Version
1.6.0.489, PC-based SpiroPerfect with CardioPerfect Work-
station software. A second sample, including 5,308
individuals from the LifeLines cohort study genotyped
at a later stage, was used to verify our initial findings.
Questionnaires, medical examinations and genotyping at
baseline were performed according to the same standard-
ized protocol in sample 1 and sample 2.
Genotyping
Genotyping was performed using IlluminaCytoSNP-12
arrays. Beagle (version 3.3) and the HapMap3-database
were used to impute additional SNPs. Three Haplotype-
tagging SNPs in the GSTO1-2 cluster with minor allele
frequency (MAF) > 0.1, HW-equilibrium p-value > 0.05,
and R2 < 0.8 were selected with Haploview (version 4.2).
We additionally included SNP rs156697 that was associ-
ated with lower FEV1 and FVC in the Framingham
Heart Study [12]. The four selected SNPs were rs4925,
rs1147611, rs156697 and rs156699. LD-plot (Additional
file 1: Figure S1) and genotype frequencies (Additional
file 1: Table S1) are presented in the online supplement.
Statistical analysis
Linear regression models adjusted for age, sex, height,
weight, current smoking, ex-smoking, and packyears
smoked, were used to analyze the associations between
ETS exposure, GSTO SNPs, the interaction between ETS
and GSTOs and level of lung function (FEV1, FEV1/FVC).
Since the interactions between ETS and GSTOs may be
modified by active tobacco smoking we additionally assessed
associations in never and ever smokers separately. All
analyses were performed using SPSS version 20.0 (IBM
Corporation, USA). P-values < 0.05 (tested 2-sided) were
considered statistically significant. To examine the robust-
ness of our findings we used False Discovery Rate (FDR)
correction for multiple testing [27], taking into account
the number of tests performed for each of the exposures
(4 SNPs * 3 separate analyses (all/never/ever) * 2 outcomes
(FEV1, FEV1/FVC)).
Ethical approval
The study was approved by the Medical Ethics Committee
of the University Medical Center Groningen, Groningen,
The Netherlands (ref. METc 2007/152).
Results
Population characteristics
Characteristics of both samples 1 and 2 are shown in
Table 1. Briefly, both samples included more females
than males and more ever than never smokers. 15% of
the participants did not know whether their mother
smoked during pregnancy, and this group was excluded
in the analyses on the effect of in utero exposure on the
Table 1 Characteristics participants included in sample 1
and sample 2
Sample 1 Sample 2
(verification)
n 8128 5308
Males, n (%) 3483 (43) 2133 (40)
Age, median (min-max) 47 (18–89) 48 (21–90)
Smoking status, n (%)
Never, n (%) 3277 (40) 2154 (41)








ETS exposure, n (%)
In utero 867 (13) 559 (13)
≥ 1 hour/day 1788 (24) 1029 (21)
At the workplace 565 (7) 303 (6)
Lung function, mean (sd)
FEV1 (ml) 3412 (831) 3331 (840)
FEV1pp (%)
1 102 (14) 102 (14)
FEV1/FVC (%) 77 (7) 76 (7)
Spirometry available, n 7635 5070
The second sample (sample 2) was used to verify the initial findings from
sample 1, both samples are part of the LifeLines population-based
cohort study.
1 FEV1pp = FEV1 as percentage predicted based on reference equations
constructed by Quanjer et al. [28].
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13% reported in utero ETS exposure. Almost 25% of the
participants reported daily ETS exposure (≥1 hours), and
7% reported ETS exposure at the workplace (in 12% of the
participants this was not applicable because of unemploy-
ment; this group was coded as a separate category in the
analyses). The median level of self-reported exposure was 2
hours per day within the group with daily ETS exposure
(25th percentile = 1 hour, 75th percentile = 4 hours).
ETS exposure and level of lung function
Complete data on all covariates was available for n = 6003,
6822 and 7149 subjects for in utero ETS exposure
(excluding ‘do not know’), daily and workplace ETS
exposure respectively. In utero ETS exposure was not
associated with FEV1 and was negatively associated with
FEV1/FVC [b = −0.6% (95% CI = −1.1 ; -0.1)]. The associ-
ation with FEV1/FVC was similar for never and ever
smokers (Additional file 1: Table S2). Daily ETS exposure
(≥1 hour) was significantly associated with lower FEV1
[−37 ml (−65; -8)], and not with FEV1/FVC. Workplace
ETS exposure was significantly associated with lower
FEV1 [−43 ml (−86; 0)], and FEV1/FVC [−0.6% (−1.2 ; 0)].
Stratification by smoking status resulted in significant
associations of ETS exposure with FEV1 in never smokers
only, effect estimates being −45 ml (−91 ; 0) and −82 ml(−153 ; -11) for daily and workplace ETS respectively
(Figure 1). Daily and workplace ETS exposure were not
significantly associated with FEV1/FVC in never or ever
smokers (for all effect estimates see Additional file 1:
Table S2).
SNPs and level of lung function
Subjects heterozygous for SNP rs4925 had a significantly
higher FEV1 [23 ml (0 ; 45)] and subjects heterozygous
for rs156699 a significantly higher FEV1/FVC [0.3%
(0 ; 0.7)] than wild types. There were no other significant
associations between genotype and lung function (Additional
file 1: Table S3).
Effect of interaction between GSTO SNPs and in utero ETS
exposure on level of lung function
Mean FEV1 levels were significantly different (i.e. higher
with in utero ETS, and lower with daily and workplace
ETS exposure) in subjects carrying both minor alleles for
all four GSTO SNPs compared to wild type and heterozy-
gote genotypes (Figure 2). Therefore we used a recessive
genetic model in subsequent analyses. In utero ETS exposure
interacted with all four GSTO SNPs and these interactions
were associated with higher level of FEV1 level (Table 2),
i.e. being homozygote for the minor alleles was associated
with a higher FEV1 only in subjects that were exposed to
ETS in utero. There was no association with FEV1/FVC
(Additional file 1: Table S4). Associations were more
pronounced in never smokers, except for SNP rs156697
(Table 2). Most of these interactions remained significant
after FDR correction for multiple testing.
Effect of interaction between GSTO SNPs and adulthood
ETS exposure on level of lung function
Daily ETS exposure (≥1 hour) interacted significantly
with SNPs rs4925, rs1147611 and rs156699 and these
interactions were associated with lower FEV1 level (Table 3).
Workplace ETS interacted significantly with all four SNPs
and these interactions were associated with lower FEV1
(Table 4). In other words, being homozygote for the minor
alleles of the GSTO SNPs was associated with lower level of
lung function only in subjects that were exposed to daily
and workplace ETS exposure. Stratification by smoking
status showed that the negative interaction effects between
ETS exposure and the SNPs on FEV1 level were consistently
more pronounced in never smokers (Tables 3 and 4). No
significant interactions were found between daily and
workplace ETS exposure and the GSTO SNPs on FEV1/
FVC in the whole group, or when stratified by smoking
status (never/ever) (Additional file 1: Tables S5 and S6).
All significant interactions of the GSTO SNPs with work-
place ETS on level of FEV1 remained significant after FDR
correction for multiple testing, the interactions with daily
ETS exposure did not remain significant.
Figure 1 Mean FEV1 (liters) for non-exposed and exposed subjects stratified by smoking status (never/ever smoker). The analysis was
adjusted for sex, current smoking, packyears smoked, and centered for group specific (never/ever smokers) means for age, height and weight.
A: In utero ETS (no/yes). B: daily ETS exposure (</≥1 hr). C: ETS exposure at the workplace (no/yes).
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Population characteristics (Table 1) and genotype fre-
quencies (Additional file 1: Table S1) were similar in the
second (verification) and the first sample. Complete data
was available for n = 3914, 4527 and 4702 subjects for in
utero, daily and workplace ETS respectively. Estimates
for the negative associations of in utero, daily and work-
place ETS exposure on FEV1 and FEV1/FVC in the veri-
fication sample, were in line with associations found in
sample 1, yet did not all reach statistical significance
(Additional file 1: Table S7). Associations between theFigure 2 Mean FEV1 (liters) for non-exposed and ETS exposed subjects st
rs156699. GSTO1 SNP rs1147611 (upper row) and GSTO2 SNP rs156699 (lower
smoked, and centered for mean age, height and weight. A: In utero ETS (no/yesheterozygote genotypes for rs4925 and rs156699 with
FEV1 and FEV1/FVC respectively, found in sample 1, could
not be replicated in the second sample (Additional file 1:
Table S3).
Interaction GSTO SNPs with in utero ETS
Similar to sample 1, GSTO2 SNP rs156697 significantly
interacted with in utero ETS exposure and was associated
with a higher level of FEV1 in sample 2 (Table 5). The
other GSTO SNPs consistently had effects in the similar
direction, yet without reaching statistical significance.ratified by genotype for the two genotyped SNPs rs1147611 and
row). The analysis was adjusted for sex, current, ex-smoking, packyears
). B: daily ETS exposure (</≥1 hr). C: ETS exposure at the workplace (no/yes).
Table 2 Effects for in utero ETS exposure (no/yes), the SNPs, and the interaction of GSTO SNPs (recessive model) with
in utero ETS exposure on FEV1
FEV1 (ml) b (95% CI)
Gene Variable All Never smokers Ever smokers
N, in analysis 6003 2576 3427
GSTO1 In utero ETS −33 (−69 ; 4) −25 (−81 ; 32) −43 (91 ; 5)
rs4925 −33 (−77 ; 10) −1 (65 ; 63) −58 (−117 ; 1)
ETS*rs4925 $177 (50 ; 305)** 196 (15 ; 376)* 161 (−18 ; 340)
GSTO1 In utero ETS −40 (−77 ; -2)* −32 (−89 ; 26) −51 (−100 ; -2)*
rs1147611 −22 (−58 ; 14) 6 (−46 ; 58) −46 (−96 ; 3)
ETS*rs1147611 $177 (72 ; 283)*** $206 (47 ; 365)* 166 (25 ; 307)*
GSTO2 In utero ETS −41 (−78 ; -3)* −28 (−85 ; 30) −55 (−104 ; -6)*
rs156697 −28 (−64 ; 9) 9 (−44 ; 62) −59 (−110 ; -8)*
ETS*rs156697 $198 (90 ; 307)*** 181 (20 ; 342)* $219 (72 ; 366)**
GSTO2 In utero ETS −33 (−70 ; 3) −24 (−81 ; 32) −45 (−93 ; 4)
rs156699 −30 (−70 ; 10) −9 (−66 ; 49) −48 (−104 ; 7)
ETS*rs156699 $160 (41 ; 278)** 193 (12 ; 374)* 143 (−15 ; 300)
The linear regression model for the whole group was adjusted for sex, age, height, weight, current, ex-smoking and packyears smoked. Consequently we stratified
by smoking status (never/ever) and adjusted for the other possible confounders.
*p-value<0.05 **p-value<0.01 *** p-value<0.001.
$significant after FDR correction for multiple testing.
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Analyses in the verification sample did not show any
significant interaction or trend for interaction between
the GSTO SNPs and daily (≥1 hour) ETS exposure
(Table 5). In line with findings in sample 1, there were
clear interactions of the GSTO SNPs with workplace
ETS exposure that were associated with lower level of
FEV1, but these interactions were non-significant inTable 3 Effects for daily ETS exposure (</≥1 hr), the SNPs, an
daily ETS exposure on FEV1
Gene Variable All
N, in analysis 6822
GSTO1 Daily ETS −27 (−56;3)
rs4925 61 (−37;49)
ETS*rs4925 −115 (−209;-22)*
GSTO1 Daily ETS −25 (−55;5)
rs1147611 15 (−22;51)
ETS*rs1147611 −83 (−159;-7)*
GSTO2 Daily ETS −29 (−59;1)
rs156697 6 (−31;43)
ETS*rs156697 −59 (−137;19)
GSTO2 Daily ETS −26 (−56;3)
rs156699 6 (−35;46)
ETS*rs156699 −94 (−178;-10)*
The linear regression model for the whole group was adjusted for sex, age, height,
by smoking status (never/ever) and adjusted for the other possible confounders.
*p-value<0.05.
There were no significant effects after FDR correction for multiple testing.sample 2 (Table 5). Full results of the (stratified) ana-
lyses in sample 2 can be found in Additional file 1: Ta-
bles S8, S9 and S10.
Overall, the directions of the interactions of in utero
and workplace ETS exposure with the SNPs found in
the second (verification) sample were in line with the
first sample, but effect estimates were somewhat smaller
and not always significant.d the interaction of GSTO SNPs (recessive model) with
FEV1 (ml) b (95% CI)
Never smokers Ever smokers
2901 3921
−31 (−79 ; 16) −28 (−66 ; 10)
67 (6 ; 128)* −46 (−106 ; 15)
−153 (−306 ; 0) −72 (−192 ; 47)
−28 (−77 ; 22) −28 (−67 ; 11)
56 (5 ; 107)* −24 (−75 ; 28)
−122 (−247 ; 3) −45 (−147 ; 52)
−28 (−77 ; 22) −34 (−73 ; 5)
57 (5 ; 109)* −40 (−93 ; 12)
−127 (−252 ; -1)* −2 (−104 ; 99)
−29 (−78 ; 19) −28 (−66 ; 10)
44 (−12 ; 100) −29 (−86 ; 28)
−133 (−268 ; 2) −56 (−165 ; 54)
weight, current, ex-smoking and packyears smoked. Consequently we stratified
Table 4 Effects for workplace ETS exposure (n/y), the SNPs, and the interaction of GSTO SNPs (recessive model) with
workplace ETS exposure on FEV1
FEV1 (ml) b (95% CI)
Gene Variable All Never smokers Ever smokers
N, in analysis 7149 3051 4098
GSTO1 Workplace ETS −26 (−71 ; 20) −51 (−126 ; 25) −17 (−73 ; 40)
rs4925 8 (−34 ; 50) 78 (17 ; 138) −48 (−105 ; 9)
ETS*rs4925 $-173 (−313 ; -33)* $-281 (−498 ; -64)* −84 (−268 ; 100)
GSTO1 Workplace ETS −22 (−68 ; 25) −41 (−117 ; 36) −15 (−73 ; 43)
rs1147611 8 (−27 ; 42) 49 (0 ; 99)# −29 (−78 ; 19)
ETS*rs1147611 $-151 (−272 ; -31)* $-286 (−486 ; -87)** −65 (−218 ; 87)
GSTO2 Workplace ETS −21 (−67 ; 25) −41 (−118 ; 36) −14 (−72 ; 44)
rs156697 8 (−28 ; 44) 50 (−1 ; 100) −29 (−79 ; 20)
ETS*rs156697 $-170 (−295 ; -46)** $-287 (−486 ; -88)** −84 (−245 ; 77)
GSTO2 Workplace ETS −17 (−63 ; 28) −41 (−117 ; 35) −9 (−66 ; 48)
rs156699 6 (−32 ; 45) 43 (−12 ; 98) −26 (−79 ; 28)
ETS*rs156699 $-218 (−349 ; -87)** $-318 (−525;-111)** −140 (−311 ; 30)
The linear regression model for the whole group was adjusted for sex, age, height, weight, current, ex-smoking and packyears smoked. Consequently we stratified
by smoking status (never/ever) and adjusted for the other possible confounders.
*p-value<0.05 **p-value<0.01.
$significant after FDR correction for multiple testing.
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Main finding
This study is the first to show that GSTO SNPs interact
with ETS exposure on FEV1, findings that were significant
after FDR correction for multiple testing and replicated in
the second (verification) sample or showed similar directions
of effects. Interestingly, interactions were in opposite direc-
tions for ETS exposure in utero and during adulthood.Table 5 Verification of the interaction of GSTO SNPs (recessiv
sample 2
Gene Variable In utero ETS
N, in analysis 3914
GSTO1 ETS −45 (−91 ; 1)
rs4925 11 (−43 ; 65)
ETS*rs4925 111 (−32 ; 253)
GSTO1 ETS −49 (−96 ; -1)*
rs1147611 4 (−40 ; 47)
ETS*rs1147611 94 (−22 ; 211)
GSTO2 ETS −52 (−99 ; -5)*
rs156697 2 (−42 ; 46)
ETS*rs156697 119 (0 ; 237)*
GSTO2 ETS −46 (−92 ; 1)
rs156699 −9 (−58 ; 39)
ETS*rs156699 106 (−29 ; 241)
Effects for in utero ETS exposure (no/yes), daily ETS exposure (</≥1 hr), workplace E
model) with different types of ETS exposure on FEV1 in sample 2 (verification). The
weight, current, ex-smoking and packyears smoked.
*p-value<0.05.Results in relation to other studies
Smoking during pregnancy has been shown to reduce
tidal flow-volume ratios in healthy newborn babies [4,5]
and to reduce small airway flows in school age children
[29]. We found no significant effect of in utero ETS
exposure on level of FEV1 in adulthood in both our study
samples, which does not exclude that effects might be
present when studying more specifically small airwaye model) with different types of ETS exposure on FEV1 in
FEV1 (ml) b (95% CI)
Daily ETS Workplace ETS
4527 4702
−41 (−78 ; -4)* −40 (−98 ; 18)
15 (−36 ; 66) 33 (−17 ; 83)
25 (−93 ; 142) −163 (−390 ; 65)
−40 (−78 ; -2)* −40 (−100 ; 20)
21 (−21 ; 63) 26 (−15 ; 67)
5 (−89 ; 98) −87 (−254 ; 81)
−41 (−79 ; -4)* −38 (−98 ; 21)
17 (−25 ; 59) 28 (−13 ; 69)
17 (−79 ; 113) −99 (−269 ; 70)
−40 (−78 ; -3)* −42 (−101 ; 17)
0 (−46 ; 47) 10 (−35 ; 56)
9 (−97 ; 115) −101 (−292 ; 91)
TS exposure (no/yes), the SNPs, and the interaction of GSTO SNPs (recessive
linear regression model for the whole group was adjusted for sex, age, height,
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with other studies investigating effects of ETS exposure
during adulthood [6,7], we found daily and workplace
ETS to be associated with lower levels of FEV1, and
these effects were more pronounced in never smokers.
Our effect estimate of a 45 ml lower FEV1 level with
daily ETS exposure in never smokers was comparable
with the 35 ml (−66 ; -4) reduced FEV1 level with daily
ETS exposure of 1 to 4 hours in never smokers from
the European Community Respiratory Health Survey
(ECRHS) [7].
The homozygote mutant genotype for SNP rs156697
was not associated with the level of FEV1 in our sample,
but there was a significant interaction with in utero ETS
exposure that was associated with higher level of FEV1.
This was a robust finding that remained significant after
FDR correction for multiple testing and was moreover
significantly replicated in the verification sample. Inter-
actions between the other three SNPs and in utero ETS
exposure showed clear trends for an association with
higher level of FEV1 in both samples but only reached
significance in the first sample. Interestingly, the homo-
zygote mutant genotypes for SNPs rs4925, rs1147611,
rs156699 significantly interacted with daily ETS exposure,
and all SNPs (rs4925, rs1147611, rs156697, and rs156699)
significantly interacted with workplace ETS exposure and
were associated with lower level of FEV1 in the first sample.
The interactions with workplace ETS exposure remained
significant after FDR correction for multiple testing and
showed a clear trend for interaction in the similar direction
in the verification sample. These latter results support
previous findings that GSTO2 is a risk gene for lower
levels of FEV1 and FVC [12].
How can we reconcile that exposure to (harmful) ETS
in utero does not result in lower but higher adult level of
lung function in subjects who are homozygote mutant
for the GSTO “risk” alleles, whereas adult ETS exposure
in these individuals associates with lower lung function?
First, exposure to ETS in utero likely leads to exposure
to different substances and concentrations of substances
than ‘direct’ inhalation of ETS. It is conceivable that
substances of ETS will be ‘filtered’ by the maternal lung
and circulation, the placenta and fetal circulation. In
addition, it is also conceivable that chronic ETS during
pregnancy induces maternal changes that are important for
lung growth. For example, it is well-known that nicotine
inhaled with cigarette smoking stimulates secretion of
growth hormone in humans [30]. This is particularly
interesting because growth hormone has been shown
to stimulate lung growth as well as lung development
during the period of alveolarization [31].
Another explanation relates to exposure to ETS taking
place in completely different periods of the life-span.
Different biochemical and biological processes are involvedin lung development in utero, lung growth in childhood
and early adulthood, and lung function decline in adult-
hood. ETS may therefore cause differential and even
contradictory effects in different periods of life. For
example, oxidative stress in utero possibly does not only
damage, but is additionally necessary for cell apoptosis
during lung morphogenesis. A recent study showed that
risk genotypes for the non-synonymous SNPs rs4925
(Ala140Asp) in GSTO1 and rs156697 (Asn142Asp) in
GSTO2 reduce GSTO2 expression levels, leading to ac-
cumulation of oxidative damage [32]. Increased oxidant
levels may contribute to cell apoptosis and subsequently
better airway branching in utero, with positive effects
on FEV1 levels. This may contrast to adult life where air-
way branching has stopped and oxidative stress has pre-
dominantly negative effects, i.e. induced epithelial and
endothelial cell damage and apoptosis that may contribute
to airway wall and/or lung tissue fibrosis and subsequently
a lower level of FEV1. Obviously, different biological pro-
cesses and pathways underlie the differential effects of
ETS in utero versus later in life. However, all given ex-
planations are speculative and merit further research.
Generally we found that the interactions between daily
and workplace ETS exposure and the GSTO SNPs were
more pronounced in the never smokers. For in utero ETS
exposure this difference was less evident. These findings
might suggest that among ever smokers the effects are
somewhat overruled by the effects of personal smoking,
that may damage the lung by similar mechanisms yet with
higher doses. We were not able to test if the interaction
between GSTO SNPs and ETS was significantly different
between the never and ever smokers since we did not have
enough study power for testing this three-way interaction
between smoking status and GSTO SNPs and ETS.
We did not find consistent significant interaction effects
of the GSTO SNPs and ETS exposure on FEV1/FVC. Since
the interactions were negatively associated with FEV1 but
not with FEV1/FVC, in an additional analysis we investi-
gated effects on FVC. In line with effects on FEV1, all four
GSTO SNPs interacted positively with in utero ETS expos-
ure and negatively with workplace ETS exposure on FVC
level. Daily ETS exposure interacted negatively with the
GSTO SNPs on FVC, but these associations were not sig-
nificant. These findings suggest restrictive rather than ob-
structive effects on lung function.
Strengths and limitations
The extensive standardized characterization of the LifeLines
population and the large sample size provided the unique
opportunity to investigate gene-by-environment interac-
tions. A major strength was the inclusion of a large verifica-
tion sample that is very similar to the discovery sample.
Since the verification sample was somewhat smaller than
the identification sample, its power might have been too
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served clear trends in similar directions. Haplotype ana-
lysis did not provide additional information and was
therefore not shown. In the current study we have ad-
justed for traditional covariates related to level of lung
function. Additional adjustment for highest obtained level
of education, as proxy for socio-economic status, ever hav-
ing had a cardiovascular event or bronchodilator use did
not change our results.
A limitation of our study might be the cross-sectional de-
sign with rather crude assessment of ETS exposure, without
data on lifetime exposure and quantitative measurement of
workplace exposure. Objective measures of exposure to en-
vironmental tobacco smoking such as cotinine levels in
serum or urine were unfortunately not available. However,
the exact questions as defined in the ECRHS surveys were
used in our study, and these questions were validated in
an Italian subsample of the ECRHS. The question about
the number of hours that a person is exposed to other peo-
ple’s tobacco smoke showed a modest correlation with
serum cotinine levels, with a clear dose–response effect
between the number of hours and cotinine levels [33].
Notwithstanding this, it should be acknowledged that
using self-reports may lead to recall bias, i.e. people ex-
periencing respiratory illness are more likely to recall
and report ETS exposure.
Conclusions
Our data show that polymorphisms in GSTO genes, in-
volved in oxidative stress pathways and detoxification of
xenobiotic substances interact with ETS exposure both in
utero and in adulthood and significantly affect the level of
FEV1.
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